SNPHF News 46.1000 Santen Pharmaceutica (SNPHF)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Santen Pharmaceutica (SNPHF) 46.1000 $SNPHF

Global Glaucoma Pipeline Review, H1 2014
M2 - Tue Apr 08, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2tn556/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Merz Pharma GmbH & Co. KgaA - Ono Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Sun Pharmaceutical Industries Limited - InSite Vision Incorporated - Can-Fite BioPharma Ltd. - NicOx S.A. - Acadia Pharmaceuticals Inc. - NeoStem, Inc. - Handok Inc. - AC Immune SA - Upsher-Smith Laboratories, Inc. - Foamix Ltd. - Laboratoires Thea S.A. - Senju Pharmaceutical Co., Ltd. - Neurotech Pharmaceuticals, Inc. - Intellect Neurosciences, Inc. - SIFI S.p.A - Cancer Therapeutics CRC Pty Ltd - Mimetogen Pharmaceuticals Inc. - Icon Bioscience, Inc. - AUS Bio Limited - SK Biopharmaceuticals Co., Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute For more information visit http://www.researchandmarkets.com/research/2tn556/glaucoma

Santen Phase III Study Meets Primary Endpoint for the Treatment of Non-Infectious Posterior Segment Uveitis (NI-PSU)
Business Wire - Fri Apr 04, 8:00AM CDT
Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double-masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint.

Global Ophthalmology Drugs And Devices (Diagnostic & Surgical) Market Report 2013-2017
M2 - Thu Nov 21, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/384qp6/ophthalmology) has announced the addition of the "Global Ophthalmology Drugs And Devices (Diagnostic & Surgical) Market Report 2013-2017" report to their offering. The ophthalmology drugs and devices market is divided into four major segments, namely, surgical devices, diagnostic and monitoring devices, vision care, and drugs. The devices market is divided into applications like surgery and diagnostics. Drugs market is classified into existing treatment drugs and drugs in pipeline and the vision care market is segmented into spectacles and contact lenses. The total market is forecasted till 2017. This market is also considered by formulation types such as capsules, gels, eye drops, ointment, and eye solutions. Advancements in technologies, high prevalence rates of refractive error, cataract, and glaucoma, increasing demand for the diagnostic procedures and low compliance with pharmaceuticals will propel the devices market. However, lack of awareness of diseases like glaucoma hinders the growth of this market. The drugs market will grow at a slower pace mainly due to the combined effect of loss of patent protection for several drugs and drying pipeline. The geographies covered in this study are North America, Europe, Asia-Pacific (APAC) and Rest of the world (RoW). North America is the largest market for ophthalmology drugs and devices, followed by Europe and Asia. North America and Europe is expected to grow at a slower pace, primarily due to the economic slowdown and saturation in these markets. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Ophthalmology Devices Market 5 Global Ophthalmology Drug Market 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles Companies Mentioned - Abbott Laboratories - Alcon, Inc. - Allergan, Inc - Bausch & Lomb, Inc. - Carl Zeiss Meditec Ag - Ellex Medical Lasers Limited - Essilor International S.A - Hoya Corporation - Iridex Corporation - Johnson & Johnson - Merck & Co., Inc - Nidek Co., Limited - Novagali Pharma S.A - Novartis Ag - Pfizer, Inc - Roche Holding Ag - Santen Pharmaceutical Co., Ltd. - Staar Surgical Company - Topcon Corporation - Ziemer Group Holding Ag For more information visit http://www.researchandmarkets.com/research/38...thalmology

Diabetic Macular Edema - Pipeline Review, H2 2013 Gives a Snapshot of the Global Therapeutic Scenario for Diabetic Macular Edema
M2 - Tue Nov 05, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/jcpdr7/diabetic_macular) has announced the addition of the "Diabetic Macular Edema - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Diabetic Macular Edema - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema. Diabetic Macular Edema - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Macular Edema pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - pSivida Corp. - GlaxoSmithKline plc - Quark Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Lux Biosciences, Inc. - Novagali Pharma SA - Astellas Pharma Inc. - TheraKine Inc. - iCo Therapeutics Inc. - NicOx SA - Regeneron Pharmaceuticals, Inc. - ThromboGenics NV - Foamix Ltd. - Molecular Partners AG - Senju Pharmaceutical Co., Ltd. - Pfenex Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - Ampio Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/jc...ic_macular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Glaucoma - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2kcjq/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2013" report to their offering. 'Glaucoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Glaucoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glaucoma. Scope - A snapshot of the global therapeutic scenario for Glaucoma. - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Glaucoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Alcon, Inc. F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. QLT Inc. Advanced Cell Technology, Inc. Quark Pharmaceuticals, Inc. Santen Pharmaceutical Co., Ltd. Oxford BioMedica plc Sylentis RetinaPharma Technologies, Inc. Novagali Pharma SA Kowa Company, Ltd. Merz GmbH & Co. KGaA Ono Pharmaceutical Co., Ltd. Pfizer Inc. Sun Pharmaceutical Industries Limited InSite Vision Incorporated Can-Fite BioPharma Ltd. NicOx SA ACADIA Pharmaceuticals Inc. Lexicon Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/l2kcjq/glaucoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Uveitis - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cbbpd2/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2013" report to their offering. 'Uveitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Uveitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uveitis. Scope - A snapshot of the global therapeutic scenario for Uveitis. - A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Uveitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Uveitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Alcon, Inc. pSivida Corp. Inovio Biomedical Corporation Santen Pharmaceutical Co., Ltd. Apitope International NV Novartis AG Isotechnika Pharma Inc. TheraKine Inc. Enzo Biochem, Inc. Can-Fite BioPharma Ltd. Regeneron Pharmaceuticals, Inc. XOMA Ltd. Hanall Pharmaceutical Co., Ltd. Artielle ImmunoTherapeutics, Inc. ProtAffin Biotechnologie AG Endocyte, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/cbbpd2/uveitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Global Rheumatoid Arthritis Report - Drug Pipeline Review
M2 - Tue Sep 03, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xw6rsc/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2013" report to their offering. 'Rheumatoid Arthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. Scope - A snapshot of the global therapeutic scenario for Rheumatoid Arthritis. - A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Featured - Alcon, Inc. - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Amgen Inc. - Antares Pharma, Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Inovio Biomedical Corporation - MedImmune LLC - Isis Pharmaceuticals, Inc. - Biotest AG - Merck & Co., Inc. - Santen Pharmaceutical Co., Ltd. - Ablynx - Emergent BioSolutions Inc. - Novo Nordisk A/S - Infinity Pharmaceuticals, Inc. - Albany Molecular Research, Inc. - Plexxikon Inc. - ViaCord - arGentis Pharmaceuticals, LLC - Reliance Life Sciences Pvt. Ltd. - MediGene AG For more information visit http://www.researchandmarkets.com/research/xw6rsc/rheumatoid

Ocular Hypertension - Pipeline Review, H2 2012
M2 - Thu Aug 01, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hswq4v/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. It also provides information on the therapeutic development for Ocular Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ocular Hypertension. The information is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Ocular Hypertension. - A review of the Ocular Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ocular Hypertension pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Ocular Hypertension Overview Therapeutics Development An Overview of Pipeline Products for Ocular Hypertension Companies Involved in Ocular Hypertension Therapeutics Development Ocular Hypertension - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Aerie Pharmaceuticals, Inc - Alcon, Inc - Allergan, Inc - Asahi Kasei Pharma - Bausch & Lomb Incorporated - F. Hoffmann-La Roche Ltd - Inotek Pharmaceuticals Corporation - Kowa Company, Ltd - LABORATOIRES THEA - Novagali Pharma SA - Ono Pharmaceutical Co - QLT Inc - Santen Incorporated - Santen Pharmaceutical Co., Ltd - Senju Pharmaceutical Co - Sun Pharmaceutical Industries Limited - Sylentis For more information visit http://www.researchandmarkets.com/research/hswq4v/ocular

Allergic Conjunctivitis - Pipeline Review, H2 2012
M2 - Fri Jul 26, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bx8lxr/allergic) has announced the addition of the "Allergic Conjunctivitis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Conjunctivitis. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Allergic Conjunctivitis. - A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Allergic Conjunctivitis Overview Therapeutics Development An Overview of Pipeline Products for Allergic Conjunctivitis Allergic Conjunctivitis Therapeutics under Development by Companies Allergic Conjunctivitis Therapeutics under Investigation by Universities/Institutes Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Pre-Clinical Stage Products Comparative Analysis Allergic Conjunctivitis Therapeutics - Products under Development by Companies Allergic Conjunctivitis Therapeutics - Products under Investigation by Universities/Institutes Companies Involved in Allergic Conjunctivitis Therapeutics Development Bausch & Lomb Incorporated Allergan, Inc. Bayer HealthCare AG Santen Pharmaceutical Co., Ltd Sun Pharmaceutical Industries Limited Fovea Pharmaceuticals SA LABORATOIRES THEA Oxagen Limited Morria Biopharmaceuticals Plc Drug Profiles Allergic Conjunctivitis Therapeutics - Drug Profile Updates Allergic Conjunctivitis Therapeutics - Discontinued Products Allergic Conjunctivitis Therapeutics - Dormant Products Allergic Conjunctivitis - Product Development Milestones Featured News & Press Releases Appendix For more information visit http://www.researchandmarkets.com/research/bx8lxr/allergic

Conjunctivitis - Pipeline Review, H2 2012
M2 - Thu Jul 11, 11:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3z578/conjunctivitis) has announced the addition of the "Conjunctivitis - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the Conjunctivitis therapeutic pipeline. This report provides information on the therapeutic development for Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Conjunctivitis. 'Conjunctivitis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Conjunctivitis Overview Therapeutics Development An Overview o

Discontinuance and Abolition of Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)
GlobeNewswire - Fri Apr 26, 6:01AM CDT
Santen Pharmaceutical Co., Ltd. (the "Company" announces that at a meeting held today, its Board of Directors resolved to discontinue and abolish the "Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)" of the Company as of the close of the annual general meeting of the shareholders for the 101st fiscal year to be held on June 25, 2013 (the "Annual General Meeting of the Shareholders" , which were introduced based on the approval of the shareholders at the annual general meeting of the shareholders held on June 26, 2007, and partially revised and approved to be continued at the annual general meeting of the shareholders held on June 23, 2010 (the revised plan shall be referred to as the "Plan" . The Plan will remain effective until the close of the Annual General Meeting of the Shareholders.

Santen Ltd. Announces Change in Management Structure for U.S. Subsidiary Organization
Business Wire - Tue Mar 12, 8:00AM CDT
Santen Pharmaceutical Co., Ltd., (Osaka, Japan, Tokyo Stock Exchange: 4536) Japan's leading ophthalmic pharmaceutical company, announced today the appointment of Naveed Shams, M.D., Ph.D. as the President and CEO of Santen Inc., and Chief Scientific Officer of Santen Ltd. Prior to this new appointment, Dr. Shams was Vice President and Head of Global Clinical Development and Medical Affairs (GCD&MA). Dr. Shams received his medical degree from Dow Medical College in Karachi, Pakistan, and his Ph.D. in Microbiology & Immunology from the University of South Carolina. After completing a fellowship in Cornea and External Disease at the Schepens Eye Research Institute & Department of Ophthalmology, Harvard Medical School, he served on the Research Faculty in the Department. Dr. Shams joined Santen Inc. almost 3 years ago. His industry experience spans 19 years across multiple therapeutic areas and includes tenures with Genen

Santen Pharmaceutical Co., Ltd. and Clearside Biomedical, Inc. Enter into Financing and Research Collaboration Agreements for Posterior Ocular Disease
Business Wire - Thu Jan 31, 7:00AM CST
Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd. (Osaka, Japan, Ticker Code 4536JP), and Clearside Biomedical, Inc. announced today that Santen Ltd., the parent company of Santen Inc., has made an investment in Clearside Biomedical Inc. and has also entered into a research collaboration agreement for posterior ocular diseases. Santen will join with other investors to fund an additional $7.9 million for continued development of CLS1001 into pivotal testing and to further Clearside Biomedical's pipeline in ocular choroidal neovascularization and inflammatory diseases of the posterior segment. Santen, along with new investor Mountain Group Capital and its affiliates join current investors Hatteras Venture Partners, Georgia Research Alliance Venture Fund, and Kenan Flagler Business School Private Equity Fund.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 78

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 49

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 139

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 83

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 93

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 63

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 110

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 69

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 135

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading

Top 5 Most Recently Viewed Articles

Air Products Secures $140 Million in NASA Liquid Hydrogen Contracts

Updated Category News Views 85

Air Products Receives Significant NASA Contracts Air Products, a leading supplier in the industrial gases market, recently announced an impressive contract award from NASA valued at over $140 million. This contract aims at supplying liquid hydrogen for various NASA facilities, most notably the renowned Kennedy Space Center and other significant sites where vital space...

Continue Reading
Navigating Market Realities: A Look Ahead for Investors

Updated Category News Views 158

The Uncomfortable Truth About Market Valuations Many investors may feel uneasy hearing this, but it’s essential to face the real data regarding market potential. After analyzing the last 40 years of market information from various developed economies, including movements in China, the reality might deter those banking on robust returns in the forthcoming decade. There's...

Continue Reading
Sodexo Unveils Its Universal Registration Document for 2025

Updated Category News Views 367

Introduction to Sodexo's Fiscal 2025 Document Sodexo has made significant strides in enhancing transparency and providing essential information through its recently filed Fiscal 2025 Universal Registration Document (URD). This document, which is now accessible to investors and stakeholders, showcases the company's ongoing commitment to accountability and sustainability....

Continue Reading
Paratus Energy's Q4 2025 Results: Key Indicators to Analyze

Updated Category News Views 197

Paratus Energy Services Ltd. (PLSV) is about to drop its unaudited interim Q4 2025 financial results on February 27, 2026. But here’s the kicker—traders are left with scant intel leading into this call, and that can rattle markets. First off, let’s talk about the earnings whispers. The usual playbook includes scouring through EPS projections and revenue figures, but...

Continue Reading
Keefe Adjusts Rating for Bank of N.T. Butterfield Amid Challenges

Updated Category News Views 72

Keefe Downgrades the Bank of N.T. Butterfield Stock Rating Recently, Keefe, Bruyette & Woods revised its recommendation for Bank of N.T. Butterfield (NYSE: NTB) stock, shifting the rating from Outperform to Market Perform. The price target has also been adjusted from $44 to $41. This reflects the bank's forecast of significant net interest income (NII) challenges...

Continue Reading